These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 17100611)

  • 1. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities.
    Tomioka H
    Curr Pharm Des; 2006; 12(31):4047-70. PubMed ID: 17100611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in antituberculous drug development and novel drug targets.
    Tomioka H; Tatano Y; Yasumoto K; Shimizu T
    Expert Rev Respir Med; 2008 Aug; 2(4):455-71. PubMed ID: 20477209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for development of new antimycobacterial drugs.
    Tomioka H
    J Infect Chemother; 2000 Mar; 6(1):8-20. PubMed ID: 11810525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches.
    Tandon R; Nath M
    Mini Rev Med Chem; 2017; 17(6):549-570. PubMed ID: 27280980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs for the treatment of tuberculosis: hope and reality.
    Grosset JH; Singer TG; Bishai WR
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):1005-14. PubMed ID: 22762423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
    Tomioka H; Tatano Y; Sano C; Shimizu T
    J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis: clinical trials and new drug regimens.
    Kwon YS; Jeong BH; Koh WJ
    Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of new antituberculous agents based on new drug targets and structure-activity relationship.
    Tomioka H
    Expert Opin Drug Discov; 2008 Jan; 3(1):21-49. PubMed ID: 23480138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New trends in development of antimycobacterial compounds.
    Biava M; Porretta GC; Deidda D; Pompei R
    Infect Disord Drug Targets; 2006 Jun; 6(2):159-72. PubMed ID: 16789877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Riminophenazines against Mycobacterium tuberculosis: A Review of Studies that Might be Contenders for Use as Antituberculosis Agents.
    Bvumbi MV
    ChemMedChem; 2020 Dec; 15(23):2207-2219. PubMed ID: 32844566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.